Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

ConclusionsThe maximum tolerated dose of rucaparib is 500 mg twice daily when co-administered with bevacizumab. The plasma concentration –time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs. The randomized phase II portion of MITO 25 will further investigate rucaparib maintenance treatment with or without bevacizumab in patients with newly diagnosed stage III–IV ova rian cancer who responded to carboplatin-paclitaxel chemotherapy with or without bevacizumab.Trial RegistrationClinicalTrials.gov identifier NCT03462212; registered March 2018.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research